These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1746070)

  • 41. Improved survival prospects for patients with castration-resistant prostate cancer.
    Kirby RS; Fitzpatrick JM
    BJU Int; 2011 Mar; 107(5):697-700. PubMed ID: 21355976
    [No Abstract]   [Full Text] [Related]  

  • 42. Assessment of quality of life in patients with prostate cancer.
    Fosså SD; Aass N; Opjordsmoen S
    Semin Oncol; 1994 Oct; 21(5):657-61. PubMed ID: 7524156
    [No Abstract]   [Full Text] [Related]  

  • 43. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 44. Urologic Clinics of North America. Castrate-resistant prostate cancer. Preface.
    Kibel AS
    Urol Clin North Am; 2012 Nov; 39(4):xv. PubMed ID: 23084535
    [No Abstract]   [Full Text] [Related]  

  • 45. [Second National Symposium on Enantone. Advances in therapy of prostate cancer. Berlin, 8 June 1991].
    Urologe A; 1991 Nov; (6 Suppl):1-4. PubMed ID: 1684456
    [No Abstract]   [Full Text] [Related]  

  • 46. Hormone dependency and histological types of prostatic carcinoma.
    Schubert GF; Völter D; Ziegler H
    Int Urol Nephrol; 1981; 13(3):271-4. PubMed ID: 7327901
    [No Abstract]   [Full Text] [Related]  

  • 47. Deferred treatment in prostatic cancer.
    Newling DW; Hall RR; Powell PH
    Lancet; 1986 Aug; 2(8501):278-9. PubMed ID: 2874294
    [No Abstract]   [Full Text] [Related]  

  • 48. [Advancements in the diagnosis and therapy of prostate neoplasms. International symposium Enantone/Prostop (Leuprorelin-Depot). Hamburg, 7 March 1992].
    Urologe A; 1992 May; 31(3 Suppl):1-12. PubMed ID: 1352652
    [No Abstract]   [Full Text] [Related]  

  • 49. Prostate cancer: are we under the lee?
    Kurth KH
    Urol Res; 1997; 25 Suppl 2():S51-2. PubMed ID: 9144886
    [No Abstract]   [Full Text] [Related]  

  • 50. [Follow up and the specialist-patient relationship. Update].
    Selvaggi FP; Ditonno P; Palazzo S; Battaglia M
    Arch Ital Urol Androl; 1997; 69(5 Suppl):25-30. PubMed ID: 9477625
    [No Abstract]   [Full Text] [Related]  

  • 51. The assessment of subjective response in prostatic cancer clinical research.
    Aaronson NK
    Am J Clin Oncol; 1988; 11 Suppl 2():S43-7. PubMed ID: 3071953
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormone-refractory prostate cancer: an emerging epidemic. Proceedings from a roundtable workshop. Philadelphia, Pennsylvania, May 22, 1996.
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):1-62. PubMed ID: 9011943
    [No Abstract]   [Full Text] [Related]  

  • 53. [Treatment of hormone-dependent cancer--recent progress and problems].
    Nihon Gan Chiryo Gakkai Shi; 1988 Apr; 23(4):940-3. PubMed ID: 3204318
    [No Abstract]   [Full Text] [Related]  

  • 54. [Expectant management in localized prostatic cancer].
    Rodríguez-Rubio Vidal F; Garrido Insua S; Figueroa Murillo E
    Actas Urol Esp; 2000 Mar; 24(3):207-11. PubMed ID: 10870226
    [No Abstract]   [Full Text] [Related]  

  • 55. Future Prospects in the Management of Prostatic Carcinoma. Proceedings of a symposium. Barcelona, Spain, April 1-3, 1993.
    Eur Urol; 1993; 24 Suppl 2():1-126. PubMed ID: 7903247
    [No Abstract]   [Full Text] [Related]  

  • 56. [First national Enantone Symposium. Progress in therapy of prostatic cancer. Multicenter study: long-term follow-up].
    Fornara P
    Urologe A; 1991 May; 30(3 Suppl):10-2. PubMed ID: 1746070
    [No Abstract]   [Full Text] [Related]  

  • 57. [Galenic innovation: Enantone monthly depot preparations].
    Hübner R
    Urologe A; 1991 May; 30(3 Suppl):7-8. PubMed ID: 1746074
    [No Abstract]   [Full Text] [Related]  

  • 58. [Hormone kinetics in suppression with monthly Enantone depot preparations].
    Schilling A
    Urologe A; 1991 May; 30(3 Suppl):9. PubMed ID: 1746075
    [No Abstract]   [Full Text] [Related]  

  • 59. [Recent multicenter study protocols in the USA for patients with metastatic prostatic carcinoma].
    DeAntoni E; Crawford ED
    Urologe A; 1995 Sep; 34(5):382-8. PubMed ID: 7483154
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Advanced prostatic carcinoma--which hormone therapy when?].
    Studer UE
    Urologe A; 1995 Sep; 34(5):361-6. PubMed ID: 7483151
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.